The endocannabinoid system: An osteopathic perspective

Journal of the American Osteopathic Association

Volumn 108, Issue 10, 2008, Pages 586-600

  McPartland, John M ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO)METHYLENE]BENZENESULFONAMIDE; ACETYLSALICYLIC ACID; ALPRENOLOL; ANANDAMIDE; CANNABIDIOL; CANNABINOID RECEPTOR; CANNABIS; CIMETIDINE; CP 945598; DIAZEPAM; DRONABINOL; ENDOCANNABINOID; FLUOXETINE; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; MORPHINE; NABILONE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; PINDOLOL; PRAZOSIN; PROBIOTIC AGENT; RIMONABANT; TARANABANT; TETRAHYDROCANNABINOL; UNINDEXED DRUG; VALPROIC ACID;

AGITATION; ANTIEMETIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANXIETY; APOPTOSIS; ARTHRITIS; AUTONOMIC NERVOUS SYSTEM FUNCTION; AUTOREGULATION; BRAIN REGION; CARTILAGE DEGENERATION; CHRONIC PAIN; CLINICAL TRIAL; CONNECTIVE TISSUE; DEGENERATIVE DISEASE; DEPERSONALIZATION; DEPRESSION; DRUG MEGADOSE; DRUG POTENTIATION; DYSPHORIA; EMBRYO DEVELOPMENT; GASTROINTESTINAL MOTILITY; HEADACHE; HEART MUSCLE CONTRACTILITY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INSOMNIA; INTESTINE FUNCTION; IRRITABILITY; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MENTAL DISEASE; MIGRAINE; MYOFASCIAL PAIN; NEURAL STEM CELL; NEUROLOGIC DISEASE; NEUROPROTECTION; NOCICEPTION; NONHUMAN; OBESITY; OSTEOPATHIC MEDICINE; PAIN; PERISTALSIS; REVIEW; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SPASTICITY; SYNAPTOGENESIS;

EID: 55849132484     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: 10.7556/jaoa.2008.108.10.586     Document Type: Review

References (143)

1. Corbett AD, Henderson G, McKnight AT, Paterson SJ. 75 years of opioid research: the exciting but vain quest for the Holy Grail [review]. Br J Pharmacol. 2006;147(suppl 1):S153-S162. Available at: http://www. pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16402099. Accessed September 10, 2008.
2. Still AT. Autobiography of Andrew T. Still. Kirksville, Mo: AT Still; 1897.
3. Goldstein M. Introduction to the symposium on endorphins and neurotransmitters. J Am Osteopath Assoc. 1984;84:96-97.
4. McPartland JM. The serendipity of health and the botany of desire. In: UNITEC Research and Development Report 2001-2002. Auckland, NZ: UNITEC Press; 2002:42-43.
5. McPartland JM, Giuffrida A, King J, Skinner E, Scotter J, Musty RE. Cannabimimetic effects of osteopathic manipulative treatment. J Am Osteopath Assoc. 2005;105:283-291. Available at: http://www.jaoa.org/cgi/content/full/ 105/6/283. Accessed September 10, 2008.
6. Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, Capasso R, et al. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available preclinical data, and first human studies. Neuropharmacology. 2005;48:1154-1163.
7. Stefano GB, Salamon EJ IV. Nitric oxide and anandamide in OMT research [letter]. J Am Osteopath Assoc. 2006;106:588-589. Available at: http://www.jaoa.org/cgi/content/full/106/10/588. Accessed September 10, 2008.
8. McPartland JM, Simons DG. Myofascial trigger points: translating molecular theory into manual therapy. J Manual Manipulative Ther. 2006;14:232-239.
9. Degenhardt BF, Darmani NA, Johnson JC, Towns LC, Rhodes DC, Trinh C, et al. Role of osteopathic manipulative treatment in altering pain biomarkers: a pilot study. J Am Osteopath Assoc. 2007;107:387-400. Available at: http://www.jaoa.org/cgi/content/full/107/9/387. Accessed September 10, 2008.
10. McPartland JM. Expression of the endocannabinoid system in fibroblasts and myofascial tissues. J Bodywork Movement Ther. 2008;12:169-182.
11. Rogers FJ, D'Alonzo GE Jr, Glover JC, Korr IM, Osborn GG, Patterson MM, et al. Proposed tenets of osteopathic medicine and principles for patient care [New & Noteworthy]. J Am Osteopath Assoc. 2002;102:63-65. Available at: http://www.jaoa.org/cgi/reprint/102/2/63. Accessed September 8, 2008.
12. Mechoulam R. The pharmacohistory of Cannabis sativa. In: Mechoulam R, ed. Cannabinoids as Therapeutic Agents. Boca Raton, Fla: CRC Press; 1986:1-19.
13. Robson P. Human studies of cannabinoids and medicinal cannabis. Handb Exp Pharmacol. 2005:719-756.
14. Wood GB. The Dispensatory of the United States of America. 10th ed. Philadelphia, Pa: Lippincott and Grambo; 1854:1480.
15. Osler W, McCrae T. The Principles and Practice of Medicine. New York, NY: Appleton and Company; 1915.
16. Fishbein M. Federal regulation of medicinal use of cannabis. JAMA. 1937;108:1543-1544.
17. Okie S. Medical marijuana and the Supreme Court. N Engl J Med. 2005;353:648-651. Available at: http://content.nejm.org/cgi/content/full/353/7/ 648. Accessed September 8, 2008
18. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids [review]. AAPS J. 2005;7:E625-E654. Available at: http://www.aapsj.org/view.asp? art=aapsj070364. Accessed September 8, 2008.
19. Marinol. In: Physicians' Desk Reference. 62nd ed. Montvale, NJ: Thomson Healthcare; 2007:3271-3273.
20. Cesamet (nabilone) fact sheet. Valeant Pharmaceuticals International Web site. Available at: http://www.valeant.com/fileRepository/mediaCenter/ Cesamet_Fact_Sheet.pdf. Accessed September 8, 2008.
21. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors [review]. Pharmacol Rev. 2002;54:161-202. Available at: http://pharmrev.aspetjournals.org/cgi/content/full/54/2/161. Accessed September 10, 2008.
22. McPartland JM, Guy G. The evolution of Cannabis and coevolution with the cannabinoid receptor - a hypothesis. In: Guy GW, Whittle BA, Robson PJ, eds. The Medicinal Uses of Cannabis and Cannabinoids. London, UK: Pharmaceutical Press; 2004:71-102.
23. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77:299-318.
24. Breivogel CS, Scates SM, Beletskaya IO, Lowery OB, Aceto MD, Martin BR. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur J Pharmacol. 2003;459:139-150.
25. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, et al. Blunted psychotomimetic and amnestic effects of delta-9- tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology. 2008;33:2505-2516.
26. Zou Y, Takano H, Akazawa H, Nagai T, Mizukami M, Komuro I. Molecular and cellular mechanisms of mechanical stress-induced cardiac hypertrophy. Endocr J. 2002;49:1-13.
27. McPartland JM, Glass M, Matias I, Norris RW, Kilpatrick CW. A shifted repertoire of endocannabinoid genes in the zebrafish (Danio rerio). Mol Genet Genomics. 2007;277:555-570.
28. McPartland JM, Matias I, Di Marzo V, Glass M. Evolutionary origins of the endocannabinoid system. Gene. 2006;370:64-74.
29. McPartland JM, Norris RW, Kilpatrick CW. Tempo and mode in endocannabinoid system evolution. J Mol Evol. 2007;65:267-276.
30. Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol. 1998;359:1-18.
31. Straiker A, Mackie K. Cannabinoids, electrophysiology, and retrograde messengers: challenges for the next 5 years. AAPS J. 2006;8:E272-E276. Available at: http://www.aapsj.org/view.asp?art=aapsj080231. Accessed September 11, 2008.
32. Sugiura T, Oka S, Gokoh M, Kishimoto S, Waku K. New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. J Pharmacol Sci. 2004;96:367-375. Available at: http://www.jstage.jst.go.jp/article/jphs/96/4/367/_pdf. Accessed September 11, 2008.
33. McPartland JM, Glass M, Pertwee RG. Meta-analysis of cannabinoid ligand binding affinity and cannabinoid receptor distribution: interspecies differences. Br J Pharmacol. 2007;152:583-589.
34. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol. 2007;14:1347-1356.
35. Heimann AS, Gomes I, Dale CS, Pagano RL, Gupta A, de Souza LL, et al. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci USA. 2007;104:20588-20593. Available at: http://www.pnas.org/ content/104/51/20588. Accessed September 11, 2008.
36. Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. In: Pertwee RG, ed. Cannabinoids (Handbook of Experimental Pharmacology). Berlin, Germany: Springer-Verlag; 2005:509-554.
37. Willard FH. Nociception, the neuroendocrine immune system, and osteopathic medicine. In: Ward RC, ed. Foundations for Osteopathic Medicine. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2003:137-156.
38. Viveros MP, Marco EM, Llorente R, López-Gallardo M. Endocannabinoid system and synaptic plasticity: implications for emotional responses [review]. Neural Plast. 2007;2007:52908. Available at: http://www.hindawi.com/GetArticle.aspx?doi=10.1155/2007/52908. Accessed September 11, 2008.
39. Morisset V, Urban L. Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. J Neurophysiol. 2001;86:40-48. Available at: http://jn.physiology.org/ cgi/content/full/86/1/40. Accessed September 11, 2008.
40. Gerdeman GL, Lovinger DM. Emerging roles for endocannabinoids in long-term synaptic plasticity. Br J Pharmacol. 2003;140:781-789. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool= pubmed&pubmedid=14504143. Accessed September 11, 2008.
41. Park B, McPartland JM, Glass M. Cannabis, cannabinoids and reproduction. Prostaglandins Leukot Essent Fatty Acids. 2004;70:189-197.
42. Harkany T, Guzmán M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci. 2007;28:83-92.
43. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urbán GM, et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007;316:1212-1216.
44. Curtis MA, Faull RL, Glass M. A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain. J Chem Neuroanat. 2006;31:210-215.
45. 1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J Biol Chem. 2007;282:23892-23898. Available at: http://www.jbc.org/cgi/content/full/282/33/ 23892. Accessed September 12, 2008.
46. Jealous J. Personal Communication. Cited by: McPartland JM, Skinner E. The biodynamic model of osteopathy in the cranial field. Explore (NY). 2005;1:21-32.
47. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol. 2003;2:291-298.
48. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29:2108-2114.
49. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug [review] [published online ahead of print April 3, 2006]. Braz J Med Biol Res. 2006;39:421-429. Available at: http://www.scielo.br/scielo.php?script= sci_arttext&pid=S0100-879X2006000400001&lng=en&nrm=iso&tlng=en. Accessed September 12, 2008.
50. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy [review]. Pharmacol Rev. 2006;58:389-462. Available at: http://pharmrev.aspetjournals.org/cgi/content/ full/58/3/389. Accessed September 12, 2008.
51. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5:400-411.
52. Ashton JC. Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs. 2007;8:373-384.
53. Emboden WA. Adaptogens: a new formula for health? Osteopath Physician. August 1976;43(8):68-70,73.
54. Raduner S Majewska A, Chen JZ, Xie XQ, Hamon J, Faller B, et al. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects [published online ahead of print March 17, 2006]. J Biol Chem. 2006;281:14192-14206. Available at: http://www.jbc.org/cgi/content/full/281/20/14192. Accessed September 12, 2008.
55. Schuelert N, McDougall JJ. Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. Arthritis Rheum. 2008;58:145-153.
56. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science. 2007;316:1494-1497.
57. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA. 2006;103:696-701. Available at: http://www.pnas.org/content/103/3/696. Accessed September 12, 2008.
58. Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003;3:745-755.
59. Jordà MA, Lowenberg B, Delwel R. The peripheral cannabinoid receptor CB2, a novel oncoprotein, induces a reversible block in neutrophilic differentiation. Blood. 2003;101:1336-1343. Available at: http://bloodjournal.hematologylibrary.org/cgi/content/full/101/4/1336. Accessed September 12, 2008.
60. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci. 2007;10:870-879. Available at: http: //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid= 17558404. Accessed September 12, 2008.
61. Suplita RL II, Eisenstein SA, Neely MH, Moise AM, Hohmann AG. Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia. Neuropharmacology. 2007;54:161-171.
62. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA. 2005;102:3093-3098. Available at: http://www.pnas.org/content/102/8/3093. Accessed September 12, 2008.
63. 1 receptors may modulate fear extinction. Pharmacol Res. 2007;56:367-381.
64. Phan KL, Angstadt M, Golden J, Onyewuenyi I, Popovska A, de Wit H. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci. 2008;28:2313-2319. Available at: http://www. jneurosci.org/cgi/content/full/28/10/2313. Accessed September 12, 2008.
65. Manning BH, Martin WJ, Meng ID. The rodent amygdala contributes to the production of cannabinoid-induced antinociception. Neuroscience. 2003;120:1157-1170.
66. Weil AT, Zinberg NE, Nelsen JM. Clinical and psychological effects of marihuana in man. Science. 1968;162:1234-1242.
67. Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A. Exercise activates the endocannabinoid system. Neuroreport. 2003;14:2209-2211.
68. Blechschmidt E. Beginnings of Human Life. Berlin, Germany: Springer-Verlag; 1977.
69. Fride E. The endocannabinoid-CB(1) receptor system in pre- and postnatal life. Eur J Pharmacol. 2004;500:289-297.
70. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab. 2007;18:27-37.
71. FDA Briefing Document: New Drug Application 21-888. Zimulti (rimonabant) Tablets, 20 mg. Washington, DC: Food and Drug Administration; 2007. Available at: http://www.fda.gov/ohrms/dockets/AC/07/briefing/2007- 4306b1fda-backgrounder.pdf. Accessed September 12, 2008.
72. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370:1706-1713.
73. Cleland SJ, Sattar N. Does rimonabant pull its weight for type 2 diabetes? Lancet. 2006;368:1632-1634.
74. 1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl). 2002;159:379-387.
75. 1 receptor knockout mice. Proc Natl Acad Sci U S A. 1999;96:5780-5785. Available at: http://www.pnas.org/content/96/10/5780. Accessed September 12, 2008.
76. 1 receptors: evidence for an endocannabinoid tone in the human neocortex. Neuroscience. 2003;120:455-465.
77. Fisas A, Codony X, Romero G, Dordal A, Giraldo J, Merce R, et al. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats [published correction appears in Br J Pharmacol. 2007;151:564]. Br J Pharmacol. 2006;148:973-983. http://www.nature.com/bjp/journal/v148/n7/full/0706807a.html. Accessed September 12, 2008.
78. Qiu J. Traditional medicine: a culture in the balance. Nature. 2007;448:126-128.
79. McPartland JM, Pruitt PL. Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydrocannabinol and marijuana [review]. Altern Ther Health Med. 1999;5:57-62.
80. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3:353-359.
81. Holley SA, Takeda H. Catching a wave: the oscillator and wavefront that create the zebrafish somite. Semin Cell Dev Biol. 2002;13:481-488.
82. 1, expression follows neuronal differentiation in the early chick embryo. J Anat. 2004;205:213-218. Available at: http://www.pubmedcentral.nih.gov/ articlerender.fcgi?tool=pubmed&pubmedid=15379926. Accessed September 12, 2008.
83. Williams EJ, Walsh FS, Doherty P. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J Cell Biol. 2003;160:481-486. Available at: http://www.jcb.org/cgi/content/ full/160/4/481. Accessed September 12, 2008.
84. Galarreta M, Erdélyi F, Szabó G, Hestrin S. Electrical coupling among irregular-spiking GABAergic interneurons expressing cannabinoid receptors. J Neurosci. 2004;24:9770-9778. Available at: http://www.jneurosci.org/cgi/content/full/24/44/9770. Accessed September 12, 2008.
85. Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsaki G. Cannabinoids reveal importance of spike timing coordination in hippocampal function [published online ahead of print November 19, 2006]. Nat Neurosci. 2006;9:1526-1533.
86. Crystal JD, Maxwell KW, Hohmann AG. Cannabinoid modulation of sensitivity to time. Behav Brain Res. 2003;144:57-66.
87. O'Leary DS, Block RI, Turner BM, Koeppel J, Magnotta VA, Ponto LB, et al. Marijuana alters the human cerebellar clock. Neuroreport. 2003;14:1145-1151.
88. 1)- immunoreactive axons in the mouse hypothalamus. J Comp Neurol. 2007;503:270-279.
89. Perron RR, Tyson RL, Sutherland GR. Delta9-tetrahydrocannabinol increases brain temperature and inverts circadian rhythms. Neuroreport. 2001;12:3791-3794.
90. Steardo L, Cottone P, Sabino V, Monteleone P, Arcidiacono D, Valenti M, et al. Evidence for a regulatory role of endocannabinoid system in the rat pineal gland activity [abstract]. In: 2004 Symposium on the Cannabinoids. International Cannabinoid Research Society; 2004:76.
91. Still AT. Osteopathy: Research and Practice. Kirksville, Mo: AT Still; 1910.
92. Korr IM. The spinal cord as organizer of disease processes: some preliminary perspectives. J Am Osteopath Assoc. 1976;76:35-45.
93. Van Buskirk RL. Nociceptive reflexes and the somatic dysfunction: a model. J Am Osteopath Assoc. 1990;90:792-794,797-809. Available at: http://www.jaoa.org/cgi/reprint/90/9/792. Accessed September 12, 2008.
94. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. 1999;92:1171-1175.
95. Korr IM, Appeltauer GSL. Trophic functions of nerves. In: Beal MC, ed. 1994 Yearbook: Louisa Burns Memorial. Indianapolis, Ind: American Academy of Osteopathy; 1994:52-60.
96. Sucher BM. Palpatory diagnosis and manipulative management of carpal tunnel syndrome: part 2. 'Double crush' and thoracic outlet syndrome. J Am Osteopath Assoc. 1995;95:471-479.
97. Andrews MAW, Andrye KA, Valentine KL, Petrizzo AM, Cohen A. The ameliorative effects of osteopathic manipulative therapy (OMT) in the treatment of sciatic nerve compression. J Osteopath Med. 2003;6:39.
98. Boal RW, Gillette RG. Central neuronal plasticity, low back pain and spinal manipulative therapy. J Manipulative Physiol Ther. 2004;27:314-326.
99. Sanchez-Pastor E, Trujillo X, Huerta M, Andrade F. Effects of cannabinoids on synaptic transmission in the frog neuromuscular junction. J Pharmacol Exp Ther. 2007;321:439-445. Available at: http://jpet. aspetjournals.org/cgi /content/full/321/2/439. Accessed September 12, 2008.
100. Newman Z, Malik P, Wu TY, Ochoa C, Watsa N, Lindgren C. Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction. Eur J Neurosci. 2007;25:1619-1630. Available at: http://www3.interscience.wiley.com/cgi-bin/fulltext/118542570/HTMLSTART. Accessed September 12, 2008.
101. Sutherland AS, Wales A, eds. Contributions of Thought: The Collected Writings of William Garner Sutherland. Kansas City, Mo: Sutherland Cranial Teaching Foundation; 1967.
102. McPartland JM, Mein EA. Entrainment and the cranial rhythmic impulse [review]. Altern Ther Health Med. 1997;3:40-45.
103. Nelson KE, Sergueef N, Glonek T. Recording the rate of the cranial rhythmic impulse. J Am Osteopath Assoc. 2006;106:337-341. Available at: http://www.jaoa.org/cgi/content/full/106/6/337. Accessed September 12, 2008.
104. Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology. 2007;32:1384-1390.
105. Egertova M, Michael GJ, Cravatt BF, Elphick MR. Fatty acid amide hydrolase in brain ventricular epithelium: mutually exclusive patterns of expression in mouse and rat. J Chem Neuroanat. 2004;28:171-181.
106. 1 receptor protein expression in the rat choroid plexus: a possible involvement of cannabinoids in the regulation of cerebrospinal fluid. Neurosci Lett. 2004;364:40-42.
107. Mancall AC, DiGregorio GJ, Brill CB, Ruch E. The effect of delta-9-tetrahydrocannabinol on rat cerebrospinal fluid. Arch Neurol. 1985;42:1069-1071.
108. Adams T, Heisey RS, Smith MC, Briner BJ. Parietal bone mobility in the anesthetized cat. J Am Osteopath Assoc. 1992;92:599-600,603-610,615-622. Available at: http://www.jaoa.org/cgi/reprint/92/5/599. Accessed September 12, 2008.
109. Eagan TS, Meltzer KR, Standley PR. Importance of strain direction in regulating human fibroblast proliferation and cytokine secretion: a useful in vitro model for soft tissue injury and manual medicine treatments. J Manipulative Physiol Ther. 2007;30:584-592.
110. Cutler MJ, Holland BS, Stupski BA, Gamber RG, Smith ML. Cranial manipulation can alter sleep latency and sympathetic nerve activity in humans: a pilot study. J Altern Complement Med. 2005;11:103-108.
111. Hillard CJ, Ho WS, Thompson J, Gauthier KM, Wheelock CE, Huang H, et al. Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619. Br J Pharmacol. 2007;152:691-698.
112. Ross RA. Allosterism and cannabinoid CB(1) receptors: the shape of things to come [review]. Trends Pharmacol Sci. 2007;28:567-572.
113. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions [review]? Neuro Endocrinol Lett. 2004;25:31-39.
114. Dunnett AJ, Roy D, Stewart A, McPartland JM. The diagnosis of fibromyalgia in women may be influenced by menstrual cycle phase. J Bodywork Movement Ther. 2007;11:99-105.
115. Dietrich A, McDaniel WF. Endocannabinoids and exercise [review]. Br J Sports Med. 2004;38:536-541. Available at: http://www.pubmedcentral.nih.gov/ picrender.fcgi?artid=1724924&blobtype=pdf. Accessed September 12, 2008.
116. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology. 2005;30:508-515.
117. Watanabe S, Doshi M, Hamazaki T. n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids. 2003;69:51-59.
118. Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A. 2001;98:6402-6406. Available at: http://www.pnas.org/content/98/11/6402. Accessed September 12, 2008.
119. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13:35-37.
120. González S, Cascio MG, Fernández-Ruiz J, Fezza F, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res. 2002;954:73-81.
121. Ortiz S, Oliva JM, Pérez-Rial S, Palomo T, Manzanares J. Chronic ethanol consumption regulates cannabinoid CB1 receptor gene expression in selected regions of rat brain. Alcohol Alcohol. 2004;39:88-92. Available at: http://alcalc.oxfordjournals.org/cgi/content/full/39/2/88. Accessed September 12, 2008.
122. Nomura DK, Blankman JL, Simon GM, Fujioka K, Issa RS, Ward AM, et al. Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008;4:373-378.
123. McPartland JM, Blanchon D, Musty RE. Cannabimimetic effects modulated by cholinergic compounds. Addict Biol. 2008;13:411-415.
124. Fowler CJ. Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. Trends Pharmacol Sci. 2004;25:59-61.
125. Guindon J, LoVerme J, De Léan A, Piomelli D, Beaulieu P. Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? Eur J Pharmacol. 2006;550:68-77.
126. Högestätt ED, Jönsson BA, Ermund A, Andersson DA, Björk H, Alexander JP, et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem. 2005;280:31405- 31412. Available at: http://www.jbc.org/cgi/content/full/280/36/31405. Accessed September 12, 2008.
127. Mallet C, Daulhac L, Bonnefont J, Ledent C, Etienne M, Chapuy E, et al. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia [published online ahead of print May 15, 2008]. Pain. 2008;139:190-200.
128. Wang S, Lim G, Mao J, Sung B, Yang L, Mao J. Central glucocorticoid receptors regulate the upregulation of spinal cannabinoid-1 receptors after peripheral nerve injury in rats. Pain. 2007;131:96-105.
129. Hill MN, Ho WS, Sinopoli KJ, Viau V, Hillard CJ, Gorzalka BB. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology. 2006;31:2591-2599.
130. Oliva JM, Urigüen L, Pérez-Rial S, Manzanares J. Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in the rat brain. Neuropharmacology. 2005;49:618-626.
131. Naderi N, Haghparast A, Saber-Tehrani A, Rezaii N, Alizadeh AM, Khani A, et al. Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol Biochem Behav. 2008;89:64-75.
132. Goffin K, Bormans G, Casteels C, Bosier B, Lambert DM, Grachev ID, et al. An in vivo [18F]MK-9470 microPET study of type 1 cannabinoid receptor binding in Wistar rats after chronic administration of valproate and levetiracetam. Neuropharmacology. 2008;54:1103-1106.
133. Burstein SH, Hunter SA. Stimulation of anandamide biosynthesis in N-18TG2 neuroblastoma cells by delta 9-tetrahydrocannabinol (THC). Biochem Pharmacol. 1995;49:855-858.
134. Rakhshan F, Day TA, Blakely RD, Barker EL. Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther. 2000;292:960-967. Available at: http://jpet.aspetjournals.org/cgi /content/full/292/3/960. Accessed September 12, 2008.
135. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134:845-852. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid= 11606325. Accessed September 12, 2008.
136. Cichewicz DL, Haller VL, Welch SP. Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine. J Pharmacol Exp Ther. 2001;297:121-127. Available at: http://jpet.aspetjournals.org/cgi/content/full/ 297/1/121. Accessed September 12, 2008.
137. Chavkin C, McLaughlin JP, Celver JP. Regulation of opioid receptor function by chronic agonist exposure: constitutive activity and desensitization. Mol Pharmacol. 2001;60:20-25. Available at: http://molpharm. aspetjournals.org/cgi/content/full/60/1/20. Accessed September 12, 2008.
138. McPartland JM, Pruitt PL. Medical marijuana and its use by the immunocompromised. Altern Ther Health Med. 1997;3:39-45.
139. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66:234-246.
140. Potter DJ, Clark P, Brown MB. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci. 2008;53:90-94.
141. Russo EB. The solution to the medicinal cannabis problem. In: Schatman ME, ed. Ethical Issues in Chronic Pain Management. New York, NY: Informa Healthcare USA; 2007:165-194.
142. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors [published ahead of print July 2, 2008]. Pain.
143. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther. 2004;311:441-448. Available at: http://jpet. aspetjournals.org/cgi/content/full/311/2/441. Accessed September 12, 2008.